/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE
TSX VENTURE EXCHANGE: JV.P
TORONTO, April 15 /CNW/ - Further to the press releases dated February
15, 2011 and March 2, 2011, J5 Acquisition Corp. ("J5") announces, in
connection with the previously announced qualifying transaction with
Trimel BioPharma Holdings Inc. (the "Qualifying Transaction"), that it
has received shareholder approval for all of the resolutions set forth
in J5's management information circular dated March 16, 2011 which
circular is posted on SEDAR.
Completion of the Qualifying Transaction is subject to a number of
conditions including, but not limited to, regulatory approvals and TSX
Venture Exchange acceptance. There can be no assurance that the
Qualifying Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the non-offering
prospectus to be prepared in connection with the Qualifying
Transaction, any information released or received with respect to the
Qualifying Transaction may not be accurate or complete and should not
be relied upon.
Investors are cautioned that trading in the securities of a CPC should
be considered highly speculative.
J5 is a CPC governed by the policies of the TSX Venture Exchange. J5's
principal business is the identification and evaluation of assets or
businesses with a view to completing a Qualifying Transaction.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE J5 Acquisition Corp.
For further information:
Ron D. Schmeichel, Chief Executive Officer of J5, at (416) 972-6294